Gartner Blog Network

Michael Shanler
Research VP
5 years at Gartner

Michael Shanler covers life science R&D technologies. Read Full Bio

Hey Ya! Cool Vendors in R&D is out…

by Michael Shanler  |  May 22, 2017

“…Now what’s cooler than bein’ cool? (Ice cold!)…” – André “André 3000” Benjamin from OutKast André 3000″ is the 9th most influential rapper of all time  according to Rateyourmusic.com.  He’s in an elite class with such influential heavy weights as 2Pac, IceCube and Jay Z.   What I like most about him is his ability to bring […]

Read more »

Hype Cycle for Life Science R&D

by Michael Shanler  |  July 25, 2016

This year, we unveiled a brand new hype cycle, one that is 100% Life Science R&D-focused. “… the moon does not present the same face every day. It waxes, or grows larger, until it becomes a glowing silver-white disk. Then night by night it wanes, or shrinks, to a curved sliver until it vanishes altogether…”  Read more: http://www.mythencyclopedia.com/Mi-Ni/Moon.html#ixzz4FQy2w1zm This […]

Read more »

Hype Cycle for 3D Printing is Out

by Michael Shanler  |  July 22, 2016

People are doing a hell of a lot more than 3D-printing personalized bobble heads and cheap chess pieces.   Granted, there is still a lot of “hype” about the technologies… but many of us  have already experienced the impacts of 3DP without even realizing it. We’ve walked in shoes with 3DP soles. We’ve been driven in […]

Read more »

Mutate the DNA of Pharma Externalization

by Michael Shanler  |  May 12, 2016

Here’s a prediction.  Life Science CxOs that continue to oversimplify “externalized innovation” strategies are in for a career-ending surprise in a few years.   For details, check this out:  Industry Visions: Life Science R&D as a Digital Innovation Orchestration Engine.  A generation ago, before the “patent cliff,” we heard from investment analysts about how “externalized […]

Read more »

R&D Cool Vendor Landscaping

by Michael Shanler  |  May 1, 2016

A few days ago, we released the R&D Cool Vendors list.   Similar to selecting the right plants for our yard, filtering the right technology-based vendors for this report required a fair bit of attention.  We sought vendors that enable “Digital R&D” and innovation strategies that: Operate at the intersection of scientific, laboratory and engineering-related processes; Leverage […]

Read more »

Cool Vendors in Life Science

by Michael Shanler  |  April 18, 2016

Allegra, Benadryl, Sudafed, Flonase, Claritin, Zyrtec, Tavist…. Why mention these drugs at this point in time?   Well…Spring is finally here.    Each season many of us spend some quality time with those little allergy pills…..  using them to try to squint through the annoying blurriness or reduce the itchiness.   We use them to attempt to gain […]

Read more »

Dealing with Electronic Trial Masterphobia…

by Michael Shanler  |  April 5, 2016

There’s an eTMF monster hiding under the bed… Well, not really…but I did recently have a conversation with a pharma R&D CIO (btw- he pre-approved me to blog about this) who mentioned that his clinical and TMF stakeholders were afraid of the consequences of moving away from a hastily implemented, resource-intensive, SP-based solution onto a new […]

Read more »

Hey Pharma, Did you listen to Elon?

by Michael Shanler  |  April 3, 2016

The Tesla Model 3 was unveiled a few days ago.  There are already over 250,000 people plopping down $1,000 deposits to reserve a product they haven’t physically seen or touched yet.  This reminds me of those Apple frenzies regarding iPhone launches.  What could be so interesting and disruptive that rational people would do something like […]

Read more »

“Accelerating R&D” Key Initiatives for Life Science Manufacturers 2016

by Michael Shanler  |  January 27, 2016

Before each calendar year begins, we put a lot of effort into outlining areas of research and how these areas align with strategic key initiatives (KIs).  The life science-related  KIs for CIOs and IT leaders have been broken into several disciplined areas: Commercial (i.e. How to more effectively market optimal therapies and services to different […]

Read more »

IDMP Compliance Storm is Brewing for Pharma in the EU

by Michael Shanler  |  January 25, 2016

As we dig out in the US from the Winter Storm “Jonas” (aka #Snowmaggedon, #Snowpocalpyse #Blizzgazzhi, #Blizzard2016) and deal with snarled traffic, delayed flights and rescheduled meetings…it reminds me that the  IDMP compliance “storm” will arrive in similar fashion.  It will be forceful, messy, confusing.  Folks need to be prepared with what is predicted on […]

Read more »